EpiCept Corporation Message Board
-
New market advantage Ceplene: Pfizer failed in AML
Pfizer had to take it s AML product 'Mylotarg from the market. FDA: Serious safety concerns, no long-term efficacy, but a trend towards more deaths. Therefore quite different to Ceplene.
Should have a positive impact for Ceplene's FDA submission: No virtual AML alternative. BTW: This Pfizer drug had an accelerated FDA approval.
Hopefully our EPCT mgmt clowns will grasp this time the chance, and do not screw it up.-
pathfinder, we talk about diamonds in the hands of pocket thieves. Talley is killing the share price and self-service Soprano rewards him for that with a higher salary. You can call their game stockholder fraud.
- 1 Reply to samur999
-
Don't say that you were fooled.
Now starts a journey. It will not be strait, but do not hesitate about the main direction.
You now have the time to leave the bitterness behind. Grab it - or leave.
Am I clear enough?
-
> Hopefully our EPCT mgmt clowns will grasp this time the chance, and do not screw it up. <
In fact, that's the problem. Talley & Savage board represent a unique mixture of impudent greediness and technical incompetence
Looks like the BP disaster- 1 Reply to gunvaldst
-
gunvalst,
We have read your anger here on Yahoo for a year now. This is the only CO you seems to follow / write about.
Do you recommened your readers to buy or sell Epicept in todays trading?
-
Nice to hear some serious thought, Pathfinder.
Here some more for the one's who pay interest:
http://diabetes.diabetesjournals.org/content/57/6/1556.full.pdf+html- 1 Reply to larshansson18
-
Sorry, I brought you the old link, this is the new one from June 2010:
http://www.ncbi.nlm.nih.gov/pubmed/20332344
-